Muscular atrophy inhibitory composition
Specific peptides with defined amino acid sequences address muscle atrophy by inhibiting muscle thinning, providing a non-exercise-based solution for maintaining muscle strength and preventing conditions like sarcopenia and frailty.
Patent Information
- Application Number
- JP2023084787
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-23
- Publication Date
- 2024-12-05
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing methods for preventing muscle atrophy, particularly due to aging, inactivity, and diseases, are inadequate, especially for individuals who cannot engage in physical exercise, leading to a decline in muscle strength and quality of life.
A composition containing specific peptides with amino acid sequences (SEQ ID NOs: 1 to 3) or modified versions (with added, deleted, or substituted residues) that inhibit muscle atrophy, which can be administered as food or pharmaceutical products.
The peptides effectively suppress muscle atrophy by maintaining or enhancing muscle thickness and mass, offering a non-mechanical treatment option for conditions like sarcopenia and frailty, with potential applications in food and pharmaceutical formulations.
Smart Images

Figure 2024168267000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to a novel peptide and a peptide having muscle atrophy inhibitory activity. [Background technology]
[0002] Skeletal muscles account for approximately 40% of an adult's body weight and are involved in maintaining smooth movement and posture by coordinating joint movement. They also play an important role in maintaining body temperature through heat production and regulating blood sugar as a target organ for insulin. Skeletal muscles atrophy and their function declines due to aging, inactivity (bed rest, plaster cast immobilization), exposure to a weightless environment, denervation, disease, etc. Skeletal muscle atrophy leads to a decline in motor ability, eventually causing problems with daily life movements and reducing quality of life (QOL). Therefore, measures to prevent muscle atrophy are an important issue for maintaining and improving QOL.
[0003] In Japan, which is becoming a super-aging society, "frailty" is considered to be a problem as a precursor to the elderly becoming dependent on nursing care. "Frailty" refers to a state of weakness between a healthy state and a state of impaired daily function or a state of nursing care, in which vulnerability to stress increases due to a decrease in physiological reserve in old age (Non-Patent Document 1). A decrease in muscle strength is one of the evaluation criteria for frailty (Japanese Cardiovascular Health Study criteria: J-CHS criteria), and sarcopenia, a state in which muscle mass is reduced (muscle atrophy) and muscle strength is reduced due to aging, is considered to be a physical aspect that leads to frailty. Therefore, suppressing muscle atrophy is also important from the perspective of preventing and improving sarcopenia in order to extend healthy lifespan.
[0004] In general, exercise therapy using muscle training is considered to be effective for muscle atrophy. However, when motor ability declines due to muscle atrophy, physical exercise becomes difficult, and effective muscle training is often not possible. In addition, muscle atrophy can lead to a vicious cycle in which the amount of movement decreases, further worsening the condition. Therefore, there is a demand for non-mechanical treatments, i.e., methods of ingesting ingredients effective against muscle atrophy in the form of foods or medicines.
[0005] To date, soybean peptides have been proposed as an effective ingredient for suppressing muscle atrophy and can be ingested in the form of food or medicine (Patent Documents 1 to 3). Collagen or gelatin, or peptides obtained by hydrolyzing these, have also been disclosed as active ingredients in muscle atrophy inhibitors (Patent Document 4). Milk-derived basic protein fractions or milk-derived basic protein fraction hydrolysates have also been disclosed as ingredients that prevent muscle atrophy (Patent Document 5). Furthermore, a peptide mixture having a specific amino acid sequence has also been disclosed as an active ingredient in muscle atrophy inhibitors (Patent Document 6). [Prior art documents] [Patent documents]
[0006] [Patent Document 1] JP 2008-013468 A [Patent Document 2] JP 2016-44146 A [Patent Document 3] JP 2019-48775 A [Patent Document 4] International Publication No. 2014 / 030514 [Patent Document 5] JP 2014-193821 A [Patent Document 6] JP 2016-160183 A [Non-patent literature]
[0007] [Non-Patent Document 1] Statement by the Japan Geriatrics Society https: / / jpn-geriat-soc.or.jp / info / topics / pdf / 20140513_01_01.pdf Summary of the Invention [Problem to be solved by the invention]
[0008] An objective of the present invention is to provide a peptide having muscle atrophy inhibitory activity. [Means for solving the problem]
[0009] As a result of intensive research aimed at solving the above problems, the present inventors have found that peptides containing specific amino acid sequences have the effect of inhibiting myotube narrowing. Based on this, they have come up with the idea that these peptides can be used as active ingredients in compositions for inhibiting muscle atrophy, and have completed the present invention.
[0010] That is, a first aspect of the present invention is a composition for inhibiting muscle atrophy, comprising one or more peptides selected from the group consisting of (a) and (b) below: (a) a peptide consisting of an amino acid sequence set forth in any one of SEQ ID NOs: 1 to 3 (b) A peptide having an amino acid sequence in which one or several amino acid residues are substituted, deleted, or added in the amino acid sequence set forth in any one of SEQ ID NOs: 1 to 3 and having muscle atrophy inhibitory activity. In this embodiment, the selected peptide is preferably a peptide as described in (a) above. The composition of this embodiment is preferably a medicine or a food or drink.
[0011] A second aspect of the present invention is a peptide selected from the group consisting of the following (a') and (b'): (a') A peptide consisting of an amino acid sequence set forth in any one of SEQ ID NOs: 2 to 3. (b') A peptide consisting of an amino acid sequence in which one or several amino acid residues have been substituted, deleted, or added in the amino acid sequence set forth in any one of SEQ ID NOs: 2 to 3 (excluding the peptide consisting of the amino acid sequence set forth in SEQ ID NO: 1). In this embodiment, the peptide is preferably a peptide according to (a'). The composition of this embodiment is preferably a medicine or a food or drink. Effect of the Invention
[0012] Since the peptide of the present invention has an excellent muscle atrophy suppressing effect, it can be made into a composition for suppressing muscle atrophy in the form of a pharmaceutical composition, food or drink, etc. [Brief description of the drawings]
[0013] [Figure 1] Graph showing myotube diameter in myoblasts cultured with a peptide-containing test sample (blank control group is set at 100%). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0014] The present invention will now be described in detail. However, the present invention is not limited to the following embodiments and can be freely modified within the scope of the present invention.
[0015] The composition for muscle atrophy of the present invention contains as an active ingredient one or more peptides selected from the group consisting of (a) and (b) below (hereinafter also referred to as "the peptide of the present invention"). (a) a peptide consisting of an amino acid sequence set forth in any one of SEQ ID NOs: 1 to 3 (b) An amino acid sequence in which one or several amino acid residues are substituted, deleted, or added in the amino acid sequence set forth in any one of SEQ ID NOs: 1 to 3, and which inhibits muscle atrophy. Peptides with Actions
[0016] Among these, peptides selected from the group consisting of the following (a') and (b') have been newly discovered. (a') A peptide consisting of an amino acid sequence set forth in any one of SEQ ID NOs: 2 to 3. (b') A peptide consisting of an amino acid sequence in which one or several amino acid residues have been substituted, deleted, or added in the amino acid sequence set forth in any one of SEQ ID NOs: 2 to 3 (excluding the peptide consisting of the amino acid sequence set forth in SEQ ID NO: 1).
[0017] In this specification, SEQ ID NOs: 1 to 3 respectively refer to the following amino acid sequences. SEQ ID NO: 1: Ala-Pro-Phe-Pro-Glu-Val-Phe (APFPEVF) SEQ ID NO: 2: Ala-Pro-Phe-Pro-Glu-Val-Phe-Gly-Lys-Glu (APFPEVFGKE) SEQ ID NO: 3: Ser-Leu-Pro-Gln-Asn-Ile-Pro-Pro-Leu-Thr-Gln-Thr-Pro-Val-Val-Val-Pro-Pro-Phe(SLPQNIPPLTQTPVVVPPF)
[0018] Here, Ala (A) represents an alanine residue, Pro (P) represents a proline residue, Phe (F) represents a phenylalanine residue, Glu (E) represents a glutamic acid residue, Val (V) represents a valine residue, Gly (G) represents a glycine residue, Lys (K) represents a lysine residue, Ser (S) represents a serine residue, Leu (L) represents a leucine residue, Gln (Q) represents a glutamine residue, Asn (N) represents an asparagine residue, Ile (I) represents an isoleucine residue, and Thr (T) represents a threonine residue. Each amino acid is preferably an L-amino acid.
[0019] Regarding the above (b) or (b'), the positions at which the amino acid residues are substituted, deleted or added are not particularly limited as long as the peptide has muscle atrophy inhibitory activity. Preferably, the amino acid residues are added to the N-terminus and / or C-terminus of the amino acid sequence set forth in any one of SEQ ID NOs: 1 to 3. The number of amino acid residues to be substituted, deleted or added is not particularly limited as long as the peptide has muscle atrophy inhibitory activity. The number of amino acid residues to be substituted, deleted or added may be, for example, 1 to 10, 1 to 5, 1 to 3, or even 1. Furthermore, the amino acid residues to be substituted, deleted or added are not particularly limited, so long as the peptide has the muscle atrophy inhibitory effect. The "muscle atrophy inhibitory effect" will be described later.
[0020] The peptide of the present invention may be in the free form or in the form of a salt thereof. Examples of the salt include salts with alkali metals such as potassium and sodium, and salts with alkaline earth metals such as calcium and magnesium. The peptide may also be in the form of an acid addition salt such as hydrochloride, lactate, ascorbate, malate, etc.
[0021] As the peptide to be contained in the composition for inhibiting muscle atrophy of the present invention, (a) a peptide consisting of an amino acid sequence set forth in any one of SEQ ID NOs: 1 to 3 is particularly preferred.
[0022] The peptide of the present invention can be obtained, for example, by: (1) hydrolyzing a protein or peptide containing a desired amino acid sequence of the peptide of the present invention with a hydrolase or the like, and isolating and purifying the resulting hydrolysis product; (2) synthesizing the peptide of the present invention by a peptide synthesis method, and then isolating and purifying the desired peptide of the present invention from the resulting crude synthesis product; and (3) synthesizing the peptide of the present invention by a method for synthesizing the peptide of the present invention. The compound can be obtained by extracting it from a plant, animal or microorganism that produces tide, and then isolating and purifying the extract obtained. Methods (1) and (2) will be specifically explained below.
[0023] (1) Hydrolysis The peptide of the present invention can be obtained by hydrolyzing a protein or peptide containing a desired sequence, for example, any one of SEQ ID NOs: 1 to 3, with a protease, acid, alkali, etc., and isolating and purifying the peptide of the present invention from the obtained hydrolysate. Examples of raw material proteins and peptides include proteins derived from milk, soybeans, peas, rice, wheat, barley, potatoes, sweet potatoes, corn, eggs, livestock meat, fish meat, seafood, etc.
[0024] A method for obtaining the peptide of the present invention by treatment with hydrolase will be described below using a typical protein as a raw material as an example, but the peptide can be obtained by appropriately modifying the method depending on the type of protein raw material. The protein raw material is a protein that contains the peptide of the present invention in its primary structure and is capable of producing the peptide of the present invention when digested with an appropriate hydrolase. First, before hydrolysis with an enzyme, the raw protein is dispersed and dissolved in water or warm water to prepare a protein aqueous solution. In order to solubilize the protein, the pH may be appropriately adjusted. The concentration of the protein aqueous solution is not particularly limited, but is usually set to a concentration of 2% by mass or more, more preferably about 5 to 30% by mass in terms of protein concentration. Furthermore, it is preferable to desalt the aqueous protein solution by an ion exchange method using a sodium or potassium type cation exchange resin (preferably a strongly acidic cation exchange resin), an electrodialysis method, an ultrafiltration membrane method, a loose reverse osmosis membrane method, or the like, and to appropriately adjust the pH and calcium concentration. Either a column method or a batch method may be used for desalting. In addition, the aqueous protein solution may be appropriately heat sterilized before desalting, etc.
[0025] The aqueous protein solution is then subjected to a hydrolysis treatment, for example, an enzyme treatment, an acid treatment, an alkali treatment, a heat treatment, etc., and two or more of these treatments may be appropriately combined. For the enzyme treatment, protease derived from plants, animals, microorganisms, etc. can be used, and one or more of these can be used in combination. As the protease, endoprotease is preferred. Examples of the endoprotease include serine proteases, metalloproteases, cysteine proteases, and aspartic acid proteases, and one or more of these may be selected and used. Among these, it is preferable to use serine proteases and / or metalloproteases. Proteases are further classified into alkaline proteases, neutral proteases and acidic proteases, of which neutral proteases are preferably used.
[0026] The protease may be a commercially available product. Examples of the protease include Sumiteam LP (manufactured by Shin Nippon Chemical Industry Co., Ltd.), Bioprase (manufactured by Nagase Chemtex Corporation), Proleather (manufactured by Amano Enzyme Co., Ltd.), Protease S (manufactured by Amano Enzyme Co., Ltd.), PTN6.0S (manufactured by Novozymes Co., Ltd.), Savinase (manufactured by Novozymes Co., Ltd.), GODO BAP (manufactured by Godo Shusei Co., Ltd.), Protease N (manufactured by Amano Enzyme Co., Ltd.), GODO BNP (manufactured by Godo Shusei Co., Ltd.), Neutrase (manufactured by Novozymes Co., Ltd.), Alcalase (manufactured by Novozymes Co., Ltd.), trypsin (manufactured by Novozymes Co., Ltd.), chymotrypsin (manufactured by Novozymes Co., Ltd.), subtilisin (manufactured by Novozymes Co., Ltd.), papain (manufactured by Amano Enzyme Co., Ltd.), bromelain (manufactured by Amano Enzyme Co., Ltd.), and the like can be included. One or more enzymes can be selected from these. It may be used.
[0027] The amount of endoprotease used relative to the protein is not particularly limited and may be appropriately adjusted depending on the substrate concentration, enzyme titer, reaction temperature, reaction time, etc., but it is generally preferable to add the endoprotease at a ratio of 100 to 30,000 activity units per gram of protein in the protein. By appropriately adjusting the conditions for hydrolysis with the protease, the desired peptide can be obtained.
[0028] Before hydrolysis with the protease, the pH of the raw material protein solution can be adjusted to the optimum pH for the enzyme to be used using food-safe salts such as potassium carbonate, sodium hydroxide, etc. The pH of the raw material protein solution is adjusted to preferably 5 to 10, more preferably 7 to 10.
[0029] The reaction temperature of the protease is desirably within the optimum temperature range for the enzyme used, preferably 30 to 70°C, and more preferably 40 to 60°C. The reaction time for the protease may be, for example, 30 minutes to 24 hours, preferably 1 to 15 hours, and more preferably 3 to 10 hours, by continuing the reaction while monitoring the decomposition rate of the enzyme reaction until a desired decomposition rate is reached. The decomposition rate is not particularly limited, but is preferably 10 to 40%.
[0030] The decomposition rate of the raw material protein is calculated by measuring the total nitrogen content of the sample using the Kjeldahl method (Food Analysis Methods, edited by the Japan Society of Food Industry, p. 102, Korin Co., Ltd., 1984) and measuring the formol nitrogen content of the sample using the formol titration method (Food Engineering Experiment Book, edited by Mitsuda et al., Vol. 1, p. 547, Yokendo, 1970), and then calculating the decomposition rate from these measured values using the following formula. Decomposition rate (%) = (formol nitrogen amount / total nitrogen amount) x 100
[0031] Hydrolysis by the protease may be terminated by heating and inactivating the enzyme. The heating temperature and holding time of the heat inactivation treatment may be appropriately set to conditions that allow sufficient inactivation, taking into consideration the thermal stability of the enzyme used. For example, it is preferable to carry out the treatment for 1 to 3 seconds when inactivating the enzyme at 100°C or higher (preferably 120 to 140°C), and for 3 to 40 minutes when inactivating the enzyme at 60°C or higher but lower than 100°C. The heat treatment may be carried out by either a batch method or a continuous method. As the continuous method, a plate heat exchange method, an infusion method, an injection method, or the like may be used. The above-mentioned heat inactivation treatment can also be used in combination with a sterilization treatment of the hydrolysate, and a conventional heat treatment method or the like can be used. After completion of the hydrolysis, the pH of the hydrolysis solution is adjusted, if necessary, to preferably 6 to 8, more preferably 7.0±0.5, and further preferably 7.0±0.3.
[0032] In the production of protein hydrolysates in the present specification, when a solution with an unadjusted calcium concentration is hydrolyzed, the resulting hydrolyzed liquid may be desalted as described above to adjust the calcium concentration. The enzyme is then inactivated by heating in a conventional manner. The reaction heating temperature and reaction holding time can be appropriately set to conditions that allow sufficient inactivation, taking into consideration the thermal stability of the enzyme used. After inactivation by heating, the enzyme is cooled in a conventional manner and can be used as it is, or can be concentrated to obtain a concentrated liquid as necessary, and the concentrated liquid can be further dried to obtain a powder product.
[0033] In addition, when the aqueous protein solution is hydrolyzed by acid treatment or alkali treatment, The treatment can be carried out by adjusting the pH of the aqueous protein solution. In the case of treatment by pH adjustment, the pH of the aqueous protein solution is preferably 5 or less or 9 or more, more preferably 4 or less or 10 or more. The aqueous solution thus pH-treated can be left or stirred at room temperature for several minutes or more, preferably 5 minutes to 1 hour, to obtain an acid-treated or alkali-treated hydrolysate. Here, "room temperature" refers to about 4 to 40°C, preferably 10 to 30°C. The protein aqueous solution may be hydrolyzed by heat treatment. The pH of the protein aqueous solution may be unadjusted or may be pH adjusted (specifically, acidic (pH 5 or less), neutral (pH 6 to 8), or alkaline (pH 8 or more)). The heat treatment may be performed at about 4 to 100° C. under the same conditions as the acid-alkali treatment.
[0034] The content of the peptide of the present invention in the protein hydrolysate is not particularly limited, but the lower limit is, from the viewpoint of better exerting the efficacy of the present invention, preferably 0.001% by mass or more, more preferably 0.005% by mass or more, and even more preferably 0.01% by mass or more, and the upper limit is, from the viewpoint of the production efficiency of the hydrolysate of the present invention, preferably 5% by mass or less, more preferably 3% by mass or less, even more preferably 2% by mass or less, and even more preferably 1.5% by mass or less.
[0035] In the present invention, the peptide content of a subject can be measured by the following method. (a) The sample powder is dissolved in a 0.1% by mass aqueous solution of formic acid to a concentration of 1.0 mg / mL, and then ultrasonically crushed for 10 minutes, filtered through a 0.22 μm PVDF filter (Millipore) to prepare a powder solution, and LC / MS analysis is performed under the following measurement conditions. Meanwhile, solutions of chemically synthesized standard peptides (Bex) of the peptide to be measured are prepared at several concentrations, and LC / MS analysis is performed under the following measurement conditions to create a calibration curve. Among the peaks in the analysis of the powder solution, those having the same molecular weight and retention time as the standard peptide are identified as having the same sequence as the standard peptide. The content of the target peptide in the powder solution is determined by comparing the peak area of the standard peptide with the peak area of the sample powder.
[0036] (b) Target peptide content (mg / g protein hydrolysate) Target peptide content (mg / g of protein hydrolysate) = [measured value of target peptide in the obtained protein hydrolysate (mg)] / [mass of the obtained protein hydrolysate (g)] [Measured amount (mg) of target peptide in the obtained protein hydrolysate] is the measured amount of the target peptide in the sample by "LC / MS" described below.
[0037] (c)LC / MS equipment used Mass spectrometer: Q Excitative Focus (Thermo Fisher Scientific) High-performance liquid chromatograph: Vanquish UHPLC system (Thermo Fisher Scientific), column: ACQUITY UPLC BEH C18 φ2.1 mm × 150 mm, 1.7 μm (Waters)
[0038] (d) LC / MS measurement conditions Mobile phase A: 0.1% by mass formic acid-water solution Mobile phase B: 0.1% formic acid-acetonitrile solution Time program: 2%B-30%B (30 min)-90%B (5 min)-2%B (1 min)-2%B (9 min) Sample injection volume: 10 μL, column temperature: 40°C, liquid flow rate: 200 μL / min Ionization mode: Positive ion mode Mass-to-charge ratio (m / z): As shown in Table 1
[0039] [Table 1]
[0040] The obtained protein hydrolysate can exert its efficacy even when used in an unpurified state. That is, the protein hydrolysate may be ingested or administered in the form of a food or beverage or pharmaceutical composition described below. Furthermore, the obtained protein hydrolysate may be subjected to appropriate separation and purification by known methods. For example, the obtained protein hydrolysate may be subjected to molecular weight fractionation to obtain a protein hydrolysate containing a fraction corresponding to the molecular weight of the peptide of the present invention. The fraction containing the target substance may be determined using the muscle atrophy inhibitory effect described below as an index. For molecular weight fractionation, for example, methods such as ultrafiltration and gel filtration can be used, which can increase the removal rate of peptides and free amino acids with unnecessary molecular weights. In the case of ultrafiltration, a desired ultrafiltration membrane may be used, and in the case of gel filtration, a desired gel filtration agent for size exclusion chromatography may be used. Furthermore, in order to desalt, remove impurities, or increase purity, known separation and purification methods, such as various types of chromatography (e.g., ion exchange chromatography, adsorption chromatography, reverse phase chromatography, partition chromatography, etc.), solvent precipitation, salting out, partition between two liquid phases, etc., may be used.
[0041] The separated and purified peptide fractions can be subjected to peptide identification by mass spectrometry to confirm whether or not they contain the peptide of the present invention. The peptide of the present invention thus obtained can be used as it is in the form of a peptide solution, or, if necessary, the solution can be concentrated by a known method to be used as a concentrate, or the concentrate can be dried by a known method to be used as a powder.
[0042] (2) Synthesis The peptides of the invention can also be produced by chemical synthesis or biosynthesis. Chemical synthesis of peptides can be carried out by a liquid phase method or a solid phase method that is commonly used for peptide synthesis. The synthesized peptide can be deprotected as necessary, and the peptide of the present invention can be isolated by removing unreacted reagents and by-products. Such peptide synthesis can be carried out using a commercially available peptide synthesizer. Peptide biosynthesis can be carried out by a conventional method, such as by introducing a peptide expression vector into a host organism and allowing the organism to produce and secrete the peptide. Whether or not the desired peptide has been obtained can be confirmed using the muscle atrophy inhibitory effect described below as an indicator.
[0043] The peptide of the present invention has an inhibitory effect on muscle atrophy. As used herein, the term "muscle atrophy" refers to muscle wasting caused by a shift in the balance between the production and degradation of skeletal muscle proteins that make up the muscle. Specifically, this refers to the narrowing of myotubes. In addition, in this specification, "suppression" refers to the improvement of symptoms or conditions of a disease in a subject to which the drug is applied, or the suppression of the disease. "Suppression" in this specification means prevention or delay of worsening of symptoms or condition of a disease, or reversal of progression, etc. Furthermore, "suppression" in this specification also includes a prophylactic meaning such as prevention or delay of onset of a disease in a subject to which the invention is applied, or reducing the risk of onset of a disease in a subject to which the invention is applied.
[0044] The term "having an inhibitory effect on muscle atrophy" means that the degree of muscle atrophy in the presence of the peptide of the present invention is smaller than that in the absence of the peptide, i.e., the state before muscle atrophy is maintained. More specifically, for example, under conditions that promote muscle atrophy (such as the presence of dexamethasone, aging, etc.), the degree of muscle atrophy in the presence of the peptide of the present invention is preferably 90% or less, more preferably 80% or less, and even more preferably 70% or less of the degree of muscle atrophy in the absence of the peptide. The degree of muscle atrophy may be indicated by the thickness of myotubes, the rate at which muscles become thinner (thinner myotubes), or muscle mass. The muscle atrophy inhibitory effect can be confirmed, for example, by the method described in the Examples below or by a standard method.
[0045] Therefore, the peptide of the present invention can be preferably contained as an active ingredient in a composition for inhibiting muscle atrophy. Here, the peptide of the present invention may be contained in the agent in the form of a protein hydrolysate, in other words, a protein hydrolysate containing one or more peptides of the present invention can be preferably contained as an active ingredient in a composition for inhibiting muscle atrophy.
[0046] The composition for inhibiting muscle atrophy of the present invention can be preferably used for the prevention, amelioration, or treatment of various muscle atrophy and diseases and symptoms associated with or involving muscle atrophy. Note that muscle atrophy and diseases and symptoms associated with or involving muscle atrophy may include unfavorable conditions at a stage before a medical diagnosis is made. Here, prevention of muscle atrophy, disease, symptoms, etc. includes preventing the onset of muscle atrophy, disease, symptoms, etc., in a subject that is not suffering from (has not developed) such disease, symptoms, etc., delaying the onset of such disease, or reducing the risk of such onset.
[0047] For example, "disuse muscle atrophy" is the most common type of muscle atrophy, which occurs when the muscle is not used for a certain period of time due to some reason, resulting in a decrease in muscle volume.Specific examples of muscle atrophy that can be applied to the muscle atrophy suppressing composition of the present invention include muscle atrophy caused by being bedridden, not exercising, or flying in zero gravity; muscle atrophy caused by immobilization of limbs during injury treatment, or postoperative rest; and the like. In addition, "age-related muscle atrophy" such as sarcopenia and the frailty caused by it can also be targets for application of the muscle atrophy-inhibiting composition of the present invention. The composition for inhibiting muscle atrophy of the present invention can also be used to treat muscle atrophy caused by some kind of damage to the muscle itself, which is called "myogenic muscle atrophy."Specific examples of such muscle atrophy include muscle atrophy observed in pathological conditions such as muscular dystrophy, congenital myopathy metabolic muscle disease, mitochondrial disease, and glycogen storage disease. The composition for inhibiting muscle atrophy of the present invention can also be used to treat muscle atrophy caused by some kind of damage to the motor neurons that supply commands and nutrients to muscles, known as "neurogenic muscular atrophy."Specific examples of such atrophy include amyotrophic lateral sclerosis (ALS), infantile spinal muscular atrophy, Charcot-Marie-Tooth disease, and congenital hypomyelination. In addition, since muscle atrophy causes muscle weakness and a decline in activities of daily living (ADL) during rehabilitation, the muscle atrophy-inhibiting composition of the present invention can also be applied to the recovery of these.
[0048] The subjects to which the peptide of the present invention is administered (recipients) and those to which the peptide is ingested (takers) are not particularly limited as long as they are animals, but are usually humans. Either sex is acceptable. In addition, there is no particular limitation on the sex. In addition, the recipient and recipient of the present invention are preferably not suffering from muscle atrophy. Here, not suffering from muscle atrophy may mean not being diagnosed by a doctor as having "disuse muscle atrophy", "myopathic muscle atrophy", or "neuropathic muscle atrophy", or may mean not meeting the criteria for muscle atrophy in various tests. When the recipient (recipient) is a human, it can be confirmed by not falling under sarcopenia according to the diagnostic criteria for sarcopenia (Guideline Asian Working Group for Sarcopenia (AWGS) 2019 or European Working Group on Sarcopenia in Older People (EWGSOP) 2), which indicates a decrease in muscle mass and muscle strength due to aging.
[0049] Another aspect of the present invention is use of the peptide of the present invention in the manufacture of a composition for inhibiting muscle atrophy. Another aspect of the present invention is the use of a peptide of the present invention in inhibiting muscle atrophy. Another aspect of the present invention is a peptide of the present invention for use in inhibiting muscle atrophy. Another aspect of the present invention is a method for inhibiting muscle atrophy, comprising administering to an animal a peptide of the present invention.
[0050] In this specification, "administering the peptide of the present invention to an animal" may be synonymous with "allowing an animal to ingest the peptide of the present invention." The ingestion may be spontaneous (free intake) or forced (forced intake). That is, the administration step may specifically be, for example, a step of blending the peptide of the present invention into food, drink, or feed and supplying it to the subject, thereby allowing the subject to ingest the peptide of the present invention freely.
[0051] The timing of intake (administration) of the peptide of the present invention is not particularly limited, and can be appropriately selected depending on the condition of the subject to be administered.
[0052] The intake (administration) amount of the peptide of the present invention is appropriately selected depending on the age, sex, condition, other conditions, etc. of the subject to be ingested (administered). The intake (administration) amount of the peptides of the present invention is preferably within the range of 1 μg / day to 200 mg / day, and more preferably within the range of 5 μg / day to 20 mg / day, for each type of peptide of the present invention for adults. Regardless of the amount or period of ingestion (administration), the peptide of the present invention can be administered once a day or in multiple divided doses.
[0053] The period of ingestion (administration) of the peptide of the present invention is not particularly limited, but is preferably 12 weeks or more, more preferably 24 weeks or more, in order to obtain the desired effect. In addition, there is no particular upper limit to the period of ingestion (administration), and continuous, long-term ingestion (administration) is possible.
[0054] The peptide of the present invention may be administered orally or parenterally, preferably orally. Parenteral administration includes transdermal, intravenous, rectal, and inhalation.
[0055] The content of the peptide of the present invention in the composition for inhibiting muscle atrophy of the present invention is preferably 0.000001% or more, more preferably 0.000005% or more, even more preferably 0.00001% or more, even more preferably 0.0001% or more, and on the other hand, is preferably 100% or less, more preferably 20% or less, and even more preferably 10% or less, for example, in the range of 0.000001% to 100%, in the range of 0.000005% to 20%, in the range of 0.00001% to 10%, in the range of 0.0001% to 10%, or in the range of 0.001% to 10%, etc.
[0056] The composition for muscle atrophy of the present invention can be in the form of a pharmaceutical product. That is, a pharmaceutical composition for preventing, improving, or treating muscle atrophy or diseases or symptoms associated with muscle atrophy or accompanied by muscle atrophy is also one aspect of the present invention. Such muscle atrophy or diseases or symptoms are as described above.
[0057] The pharmaceutical composition may be administered orally or parenterally, preferably orally. Parenteral administration includes transdermal, intravenous, rectal, and inhalation. The pharmaceutical composition can be formulated into a desired dosage form according to the administration method.For example, in the case of oral administration, it can be formulated into solid preparations such as powders, granules, tablets, and capsules; liquid preparations such as solutions, syrups, suspensions, and emulsions.In addition, in the case of parenteral administration, it can be formulated into suppositories, ointments, injections, and the like. In the formulation, in addition to the peptide of the present invention, ingredients that are usually used in formulations, such as excipients, pH adjusters, colorants, flavorings, etc., can be used. It is also possible to use other pharmaceuticals, such as other medicinal ingredients and ingredients that can prevent, ameliorate, and / or treat diseases or symptoms caused by muscle atrophy that are known or will be discovered in the future. Furthermore, other peptides may be present in combination so long as they do not impede the effects of the present invention. In addition, formulation can be carried out by a known method according to the dosage form. When formulating, a carrier usually used in formulation may be appropriately mixed. Such carriers include excipients, binders, disintegrants, lubricants, stabilizers, flavoring agents, etc.
[0058] Examples of excipients include sugar derivatives such as lactose, sucrose, glucose, mannitol, and sorbitol; starch derivatives such as corn starch, potato starch, α-starch, dextrin, and carboxymethyl starch; cellulose derivatives such as crystalline cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, carboxymethyl cellulose, and calcium carboxymethyl cellulose; gum arabic; dextran; pullulan; silicate derivatives such as light anhydrous silicic acid, synthetic aluminum silicate, and magnesium aluminometasilicate; phosphate derivatives such as calcium phosphate; carbonate derivatives such as calcium carbonate; and sulfate derivatives such as calcium sulfate.
[0059] Examples of binders include gelatin, polyvinylpyrrolidone, macrogol, and the like, in addition to the above-mentioned excipients.
[0060] Examples of disintegrants include the above-mentioned excipients, as well as chemically modified starch or cellulose derivatives such as croscarmellose sodium, sodium carboxymethyl starch, and crosslinked polyvinylpyrrolidone.
[0061] Examples of lubricants include talc; stearic acid; metal stearates such as calcium stearate and magnesium stearate; colloidal silica; waxes such as pea gum and geranium stearate; boric acid; glycol; carboxylic acids such as fumaric acid and adipic acid; sodium carboxylates such as sodium benzoate; sulfates such as sodium sulfate; leucine; lauryl sulfates such as sodium lauryl sulfate and magnesium lauryl sulfate; silicic acids such as silicic anhydride and silicic acid hydrate; starch derivatives, and the like.
[0062] Examples of the stabilizer include paraoxybenzoic acid esters such as methylparaben and propylparaben; alcohols such as chlorobutanol, benzyl alcohol, and phenylethyl alcohol; benzalkonium chloride; acetic anhydride; and sorbic acid.
[0063] Examples of flavoring agents include sweeteners, acidulants, and fragrances. In the case of a liquid preparation for oral administration, examples of the carrier used include solvents such as water.
[0064] The timing of taking the pharmaceutical composition of the present invention is not particularly limited, and may be, for example, before meals, after meals, between meals, or before going to bed, but before meals is preferable.
[0065] When the composition for muscle atrophy of the present invention is in a form to be orally ingested, it is preferably in the form of a food or drink. That is, a food or drink for preventing or improving muscle atrophy or an undesirable condition associated with muscle atrophy or accompanied by muscle atrophy is also an aspect of the present invention. In other words, the food or drink according to the present invention is a food or drink with an application related to the inhibitory effect of muscle atrophy. Such muscle atrophy or condition is as described above.
[0066] There are no particular limitations on the form or properties of the food or beverage product as long as it does not impair the effects of the present invention and can be taken orally. Other than containing the peptide of the present invention, the food or beverage product can be produced by conventional methods using raw materials typically used for food or beverage products.
[0067] Food and drink products include, regardless of their form, liquid, paste, gel, solid, powder, etc., such as tablet confectionery; liquid food (nutritional food for tube feeding); wheat flour products such as bread, macaroni, spaghetti, noodles, cake mix, fried chicken powder, breadcrumbs, etc.; instant noodles, cup noodles, retort / prepared foods, pre-cooked canned foods, microwave foods, instant soups / stews, instant miso soup / cleansing soups, canned soups, freeze-dried foods, other instant foods, etc.; canned agricultural products, canned fruit, jams / mackerels, etc. - Agricultural processed products such as malts, pickles, boiled beans, dried agricultural goods, cereals (processed grain products); processed marine products such as canned seafood, fish ham and sausage, seafood paste products, seafood delicacies, tsukudani (fried fish paste), etc.; processed livestock products such as canned livestock paste, livestock ham and sausage, etc.; dairy products such as processed milk, milk drinks, yogurt, lactic acid bacteria drinks, cheese, ice cream, modified milk powder, cream, other dairy products, etc.; fats and oils such as butter, margarines, vegetable oils, etc.; soy sauce, miso, sauces, Basic seasonings such as processed tomato seasonings, mirin, vinegar, etc.; complex seasonings and foods such as cooking mixes, curry bases, sauces, dressings, noodle soups, spices, and other complex seasonings; frozen foods such as frozen ingredient foods, semi-cooked frozen foods, and cooked frozen foods; confectioneries such as caramel, candy, chewing gum, chocolate, cookies, biscuits, cakes, pies, snacks, crackers, Japanese sweets, rice snacks, bean snacks, dessert snacks, jellies, and other confectioneries; These include carbonated drinks, natural fruit juice, fruit juice drinks, soft drinks with fruit juice, fruit pulp drinks, fruit drinks with fruit particles, vegetable drinks, soy milk, soy milk drinks, coffee drinks, tea drinks, powdered drinks, concentrated drinks, sports drinks, nutritional drinks, alcoholic drinks, and other beverages, as well as other commercially available foods such as baby food, furikake, and ochazuke nori; infant formula; enteral nutritional food; health functional foods (foods for specified health uses, foods with nutritional functions, foods with functional claims), and nutritional supplements such as supplements.
[0068] When the food or drink is in the form of a supplement, it can be formulated into solid preparations such as powders, granules, tablets, capsules, etc., which may be enteric-coated, etc.; liquid preparations such as solutions, syrups, suspensions, emulsions, etc. When formulating such preparations, the above-mentioned explanations of the ingredients, carriers, and methods for formulating pharmaceuticals can be followed.
[0069] In addition, one aspect of the food and drink may be feed, such as pet food, livestock feed, and fish feed. The form of the feed is not particularly limited, and may contain, in addition to the peptide of the present invention, for example, grains such as corn, wheat, barley, rye, milo, etc.; vegetable oil cakes such as soybean oil cake, rapeseed oil cake, palm oil cake, linseed oil cake, etc.; bran such as wheat bran, rice bran, defatted rice bran, etc.; manufacturing residues such as corn gluten meal and corn jam meal; animal feeds such as fish meal, skim milk powder, whey, yellow grease, tallow, etc.; yeasts such as torula yeast and brewer's yeast; mineral feeds such as calcium phosphate and calcium carbonate; oils and fats; simple amino acids; sugars, etc.
[0070] When the peptide of the present invention is in the form of a food or drink (including feed), it is effective in preventing muscle atrophy and other disorders associated with muscle atrophy. The peptide of the present invention described herein can be provided and sold as a food or drink labeled for use in preventing or improving unfavorable conditions associated with muscle atrophy. The peptide of the present invention described herein can be used for the production of such a food or drink.
[0071] Such "indication" acts include all acts for informing consumers of the above-mentioned uses, and any expression that can recall or infer the above-mentioned uses falls under the category of "indication" acts in this invention, regardless of the purpose of the indication, the content of the indication, the object or medium on which it is displayed, etc. Furthermore, it is preferable that the "labeling" be done in an expression that allows consumers to directly recognize the above-mentioned uses.Specific examples include the act of transferring, delivering, displaying for the purpose of transferring or delivering, or importing food and beverage products or product packaging on which the above-mentioned uses are written, displaying or distributing advertisements, price lists, or transaction documents related to the products and writing the above-mentioned uses in information containing the above-mentioned uses and providing them by electromagnetic means (such as the Internet), etc.
[0072] On the other hand, the content of the labeling is preferably a labeling approved by the government etc. (for example, a labeling approved based on various systems established by the government and made in a manner based on such approval, etc.) In addition, it is preferable that such a labeling content is affixed to the packaging, containers, catalogs, pamphlets, POP and other sales site promotional materials, other documents, etc.
[0073] In addition, "labeling" also includes labeling as health food, functional food, enteral nutrition food, special purpose food, health functional food, food for specified health uses, nutrient functional food, functional food, functional labeling food, medical drug, etc. Among these, in particular, labeling approved by the Consumer Affairs Agency, for example, labeling approved under the system related to food for specified health uses, nutrient functional food, or functional labeling food, or a similar system, etc., can be mentioned. Specifically, labeling as food for specified health uses, labeling as food for conditional specified health uses, labeling that affects the structure or function of the body, labeling for reducing disease risk, labeling of functionality based on scientific evidence, etc., can be mentioned, and more specifically, labeling as food for specified health uses (especially labeling of health uses) and similar labeling as specified in the Cabinet Office Ordinance on the Permission of Labeling for Special Uses Prescribed in the Health Promotion Act (Cabinet Office Ordinance No. 57 of August 31, 2009) are typical examples.
[0074] Examples of such labeling include "for those concerned about muscle wasting," "for those concerned about muscle atrophy," "maintaining healthy muscles," "maintaining muscle mass," "maintaining muscle mass that decreases with age," "to prevent muscle atrophy," "to improve motor function," "for those who want to prevent aging," "for those who want to extend their healthy life expectancy," etc. EXAMPLES
[0075] The present invention will be described in more detail below using examples, but the present invention is not limited to these examples.
[0076] <Evaluation of peptides' muscle atrophy inhibitory effects> Peptides consisting of the amino acid sequences shown in SEQ ID NOs: 1 to 5 were chemically synthesized by Fmoc solid-phase synthesis. After deprotection, the peptides were purified by reversed-phase HPLC and then lyophilized.
[0077] The muscle atrophy suppression effect was evaluated using the effect on myotube diameter length of C2C12 cells (CRL-1772, ATCC), a myoblast cell line derived from mouse skeletal muscle that is commonly used as a system for evaluating muscle atrophy suppression. Note that C2C12 cells are cells that differentiate into muscle cells through differentiation induction, so here, C2C12 cells before differentiation are referred to as "C2C12 progenitor cells." C2C12 progenitor cells were cultured in a 6-well cell culture plate at approximately 2.4 × 10 5 Cells were seeded at 1000 cells / well and treated with Dulbecco's Modified Eagle Medium. The cells were cultured for 24 hours at 37℃ and CO2 concentration 5% in a medium containing 1% (v / v) penicillin / streptomycin and 2 mmol / L L-Glutamine in DMEM high glucose medium (hereinafter referred to as basal medium) and 10% (v / v) Fetal Bovine Serum (FBS). After that, to induce differentiation into myotube formation, the medium was replaced with a differentiation medium containing 2% (v / v) Horse Serum in basal medium, and the cells were cultured for another 6 days at 37℃ and CO2 concentration 5%. The differentiation medium was changed every 2 or 3 days during the culture period. The differentiated C2C12 cells were supplemented with each of the following media: blank control group (basal medium), negative control group (basal medium supplemented with 10 μM dexamethasone), positive control group (basal medium supplemented with 10 μM dexamethasone and 0.2 mg / mL insulin), and test sample groups 1 to 5 (basal medium supplemented with 100 μg / mL of peptides consisting of the amino acid sequences set forth in SEQ ID NOs: 1 to 5, respectively, and 10 μM dexamethasone), and cultured for 24 hours at 37°C and 5% CO2 concentration (n=3 for each group).
[0078] After culturing, C2C12 cells were washed with D-PBS(-), and the nuclei and cytoplasm were stained with hematoxylin-eosin staining. The stained myotubes were photographed using an optical microscope equipped with a camera. Four photographs were taken for each well, and five myotubes of standard diameter were selected from each photograph. The diameter of the standard diameter of the myotubes was measured using cell Senses imaging software (OLYMPUS).
[0079] The relative values and standard deviations of the average myotube diameters of C2C12 cells in each group, when the average value of the myotube diameter of C2C12 cells in the blank control group is taken as 100%, are shown in Figure 1. For statistical analysis, a Dunnett test was performed based on the negative control group. As a result, the myotube diameter of the negative control group was significantly reduced compared to the blank control group, indicating that dexamethasone may thin myotubes and cause muscle atrophy. In addition, the relative values of the positive control group and test sample groups 1, 2, and 3 were significantly higher than those of the negative control group, confirming that the peptides contained in test sample groups 1, 2, and 3 suppress the decrease in myotube diameter induced by dexamethasone and suppress muscle atrophy. In addition, there was no significant difference between test sample groups 4 and 5 and the negative control group, confirming that these samples do not affect myotube diameter.
Claims
1. A composition for inhibiting muscle atrophy, comprising one or more peptides selected from the group consisting of (a) and (b) below: (a) a peptide consisting of an amino acid sequence set forth in any one of SEQ ID NOs: 1 to 3 (b) A peptide having an amino acid sequence in which one or several amino acid residues are substituted, deleted, or added in the amino acid sequence set forth in any one of SEQ ID NOs: 1 to 3, and having muscle atrophy inhibitory activity.
2. The composition for inhibiting muscle atrophy according to claim 1, wherein the selected peptide is the peptide described in (a).
3. The composition for inhibiting muscle atrophy according to claim 1 or 2, which is a pharmaceutical.
4. The composition for inhibiting muscle atrophy according to claim 1 or 2, which is a food or drink.
5. A peptide selected from the group consisting of (a') and (b') below. (a') a peptide consisting of an amino acid sequence set forth in any one of SEQ ID NOs: 2 to 3 (b') A peptide consisting of an amino acid sequence in which one or several amino acid residues have been substituted, deleted, or added in the amino acid sequence set forth in any one of SEQ ID NOs: 2 to 3 (excluding the peptide consisting of the amino acid sequence set forth in SEQ ID NO: 1).
6. The peptide according to claim 5, which is described in (a').
Citation Information
Patent Citations
Ubiquitin ligase inhibitor
JP2008013468A
Amyotrophy inhibitor
JP2014193821A
Muscle atrophy inhibitor and muscle growth promoter
JP2016044146A
Muscular atrophy inhibitor
JP2016160183A
Muscle atrophy inhibitor and muscle growth promoter
JP2019048775A
Cited By
Milk-derived polypeptide sequence for promoting skeletal muscle cell proliferation and application thereof
CN119613525A
